Ophthalmic Business News

In the last post, I introduced the concept of AI content engines and how they can significantly leverage your marketing efforts via multiple technologies and across multiple channels.

Like many sports, such as soccer and basketball, financial independence requires simultaneous offense and defense. One of the most important defensive plays a physician must make is buying disability insurance.

The FDA approved the Vabysmo 6-mg single-dose prefilled syringe for the treatment of wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion, according to a Genentech press release.

Alcon completed the acquisition of Belkin Vision, including its direct selective laser trabeculoplasty technology, according to a press release.

The FDA approved FYB203/Ahzantive as a biosimilar to Eylea, according to a joint press release from Formycon and Klinge Biopharma.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David Kirn, MD, of 4D Molecular Therapeutics provides an update on two candidates for retinal diseases.

Given the substantial investment to become a practicing physician, it should not be surprising that the most significant asset of most physicians is their ability to practice their profession.

The FDA granted de novo classification to the Fysx ocular pressure adjusting pump for patients with normal-tension glaucoma or open-angle glaucoma with IOP of 21 mm Hg or less, according to a press release from Balance Ophthalmics.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Octane OTF with Euan Thomson, PhD, Barry Kuppermann, MD, Jeffry Weinhuff, Ehsan Sadri, MD, FACS, and a special announcement from Rich Small.

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on the marketing authorization application for pegcetacoplan for the treatment of geographic atrophy.